全文获取类型
收费全文 | 10399篇 |
免费 | 578篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 126篇 |
儿科学 | 300篇 |
妇产科学 | 197篇 |
基础医学 | 1337篇 |
口腔科学 | 285篇 |
临床医学 | 1019篇 |
内科学 | 1981篇 |
皮肤病学 | 93篇 |
神经病学 | 1108篇 |
特种医学 | 294篇 |
外科学 | 1420篇 |
综合类 | 52篇 |
一般理论 | 6篇 |
预防医学 | 841篇 |
眼科学 | 192篇 |
药学 | 792篇 |
中国医学 | 22篇 |
肿瘤学 | 942篇 |
出版年
2023年 | 43篇 |
2022年 | 39篇 |
2021年 | 161篇 |
2020年 | 159篇 |
2019年 | 199篇 |
2018年 | 240篇 |
2017年 | 199篇 |
2016年 | 220篇 |
2015年 | 242篇 |
2014年 | 305篇 |
2013年 | 550篇 |
2012年 | 672篇 |
2011年 | 693篇 |
2010年 | 404篇 |
2009年 | 376篇 |
2008年 | 654篇 |
2007年 | 656篇 |
2006年 | 670篇 |
2005年 | 616篇 |
2004年 | 579篇 |
2003年 | 563篇 |
2002年 | 545篇 |
2001年 | 116篇 |
2000年 | 65篇 |
1999年 | 110篇 |
1998年 | 124篇 |
1997年 | 114篇 |
1996年 | 103篇 |
1995年 | 116篇 |
1994年 | 94篇 |
1993年 | 93篇 |
1992年 | 71篇 |
1991年 | 90篇 |
1990年 | 60篇 |
1989年 | 64篇 |
1988年 | 57篇 |
1987年 | 51篇 |
1986年 | 51篇 |
1985年 | 74篇 |
1984年 | 86篇 |
1983年 | 58篇 |
1982年 | 85篇 |
1981年 | 76篇 |
1980年 | 39篇 |
1979年 | 34篇 |
1978年 | 39篇 |
1977年 | 54篇 |
1976年 | 31篇 |
1975年 | 32篇 |
1973年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
1.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
2.
Erika Cecon Anna Ivanova Marine Luka Florence Gbahou Anne Friederich Jean‐Luc Guillaume Patrick Keller Klaus Knoch Raise Ahmad Philippe Delagrange Michele Solimena Ralf Jockers 《Journal of pineal research》2019,66(2)
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies. 相似文献
3.
4.
5.
6.
7.
Ulla Bergfeldt Kristian Borg Kjell Kullander Per Julin 《Journal of rehabilitation medicine》2006,38(3):166-171
OBJECTIVE: Analysis of the effects of a comprehensive focal spasticity program in adult patients. DESIGN: Retrospective study of an out-patient cohort. PATIENTS: One hundred patients were enrolled in the study (54 men and 46 women, mean age 41 years (SD 14). Cerebral palsy and stroke were equally common (80% in total). The remaining patients had miscellaneous diagnoses, including traumatic brain injury. METHODS: On average 230 units (SD 101) of botulinum toxin A Botox was given for 227 principal therapy targets chosen by the patient or the caregiver. One patient could have several targets for therapy. Administration of botulinum toxin was combined with 260 additional therapeutic interventions, most of which were forms of physical therapy. The effects were assessed after 6 weeks and compared with baseline functional abilities 1-2 weeks prior to therapy. RESULTS: Improvement was observed for 211 (93%) therapy targets, no change in 15 (7%), and impairment in 1, corresponding to an overall improvement in 90 patients (90%), 9 unchanged (9%) and worsening in 1. Spasticity assessment (Ashworth scale 0-4; 30 patients) showed a statistically significant improvement (median at baseline was 3 vs 2 after therapy, mean difference 1.2, p<0.001). CONCLUSION: Improvement was observed in >or=90% of patients and in their principal therapeutic targets in a cohort receiving their first focal spasticity treatment with botulinum toxin A and additional therapy. A strict strategy for patient selection and comprehensive management was followed. 相似文献
8.
9.
Rickard Köhnke Andreas Lindqvist Nathanael Göransson Sinan C. Emek Per‐Åke Albertsson Jens F. Rehfeld Anna Hultgårdh‐Nilsson Charlotte Erlanson‐Albertsson 《Phytotherapy research : PTR》2009,23(12):1778-1783
Thylakoids are membranes isolated from plant chloroplasts which have previously been shown to inhibit pancreatic lipase/colipase catalysed hydrolysis of fat in vitro and induce short‐term satiety in vivo. The purpose of the present study was to examine if dietary supplementation of thylakoids could affect food intake and body weight during long‐term feeding in mice. Female apolipoprotein E‐deficient mice were fed a high‐fat diet containing 41% of fat by energy with and without thylakoids for 100 days. Mice fed the thylakoid‐enriched diet had suppressed food intake, body weight gain and body fat compared with the high‐fat fed control mice. Reduced serum glucose, serum triglyceride and serum free fatty acid levels were found in the thylakoid‐treated animals. The satiety hormone cholecystokinin was elevated, suggesting this hormone mediates satiety. Leptin levels were reduced, reflecting a decreased fat mass. There was no sign of desensitization in the animals treated with thylakoids. The results suggest that thylakoids are useful to suppress appetite and body weight gain when supplemented to a high‐fat food during long‐term feeding. Copyright © 2009 John Wiley & Sons, Ltd. 相似文献
10.
Birgitta Malmberg Göran Kecklund Björn Karlson Roger Persson Per Flisberg Palle Ørbaek 《BMC health services research》2010,10(1):239